Clinical trial · no report yet · Phase 3
NCT05197192
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- NCT05197192 ↗
- Recruiting
- German CLL Study Group
- 27 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 8 | |
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk Chronic Lymphocytic Leukemia (CLL)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Obinutuzumab; Venetoclax; Acalabrutinib
- Arms
- GAVe-Arm · Experimental
- GVe-Arm · Experimental
- Enrollment
- 202 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- German CLL Study Group with AstraZeneca
- Start
- Apr 19, 2022
- Primary completion
- May 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05197192 · updated Aug 20, 2026